Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer.

Autor: Swami U; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Antonarakis ES; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Electronic address: eantona1@jhmi.edu., Agarwal N; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.

Publikováno v: European urology [Eur Urol] 2021 Mar; Vol. 79 (3), pp. e94-e95. Date of Electronic Publication: 2021 Jan 06.

Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview

Autor: Rodolfo Borges dos Reis MD, PHD, José L. Aguilar-Ponce MD, Federico Cayol MD, MSc, Angela M. Jansen PhD, MHS, Ray Manneh K MD, MSc, Tomas R Merino MD, Gayatri Sanku PhD, MPH, Laura B. Vaca MD, Pedro Isaacsson Velho MD, Ernesto P. Korbenfeld MD

Publikováno v: Cancer Control, Vol 31 (2024)

In Latin America, prostate cancer is the third most common cancer overall and the most common in men, with the highest mortality rate of all cancers. In 2022, there were approximately 22,985 new prostate cancer cases and 61,056 deaths from prostate c

Externí odkaz: https://doaj.org/article/02d40ef4d4894cab8a0974095637a926

The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol

Autor: Jeziel Basso, Juliana Beust de Lima, Marina Bessel, Santiago Alonso Tobar Leitão, Thais Machado Baptista, Sergio Roithmann, Eduardo Franco Carvalhal, Caio da Silva Schmitt, Ivan Morzoletto Pedrollo, Alice Schuch, Antonio Atalibio Hartmann, Carmen Liane Neubarth Estivallet, Guilherme Behrend Silva Ribeiro, Ricardo Andre Zordan, Pedro Isaacsson Velho

Publikováno v: BMC Urology, Vol 23, Iss 1, Pp 1-6 (2023)

Abstract Background Prostate cancer exhibits a very diverse behaviour, with some patients dying from the disease and others never needing treatment. Active surveillance (AS) consists of periodic PSA assessment (prostate-specific antigen), DRE (digita

Externí odkaz: https://doaj.org/article/019a1eb681324b1db305473aaa9cb4dc

Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire

Autor: Nima Nabavi, Seied Rabi Mahdavi, Mohammad Afshar Ardalan, Mohsen Chamanara, Reza Mosaed, Aline Lara, Diogo Bastos, Sara Harsini, Emran Askari, Pedro Isaacsson Velho, Hamed Bagheri

Publikováno v: Biomedicines, Vol 11, Iss 7, p 2084 (2023)

Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer treatment. However, the progression towards castration-resistant prostate cancer is inevitable, as the cancer cells reactivate androgen receptor signaling and adap

Externí odkaz: https://doaj.org/article/5aa20dcaf14041718ded79d4ccf09c1e

Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability

Autor: Aline B.L. Gongora, Catherine H Marshall, Pedro Isaacsson Velho, Carlos D.H. Lopes, José F. Marin, Anamaria A. Camargo, Diogo A. Bastos, Emmanuel S. Antonarakis

Publikováno v: Clinical Genitourinary Cancer. 20:183-188

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::17b4f85418096fb053c27770c05e65a9
https://doi.org/10.1016/j.clgc.2021.11.015